Efficacy of anti-HER2 agents in combination with adjuvant or neoadjuvant chemotherapy for early and locally advanced HER2-positive breast cancer patients : a network meta-analysis

• Autor(a) principal: Debiasi, Márcio
• Data de Publicação: 2018
• Outros Autores: Polanczyk, Carisi Anne, Ziegelmann, Patricia Klarmann, Barrios, Carlos Henrique Escosteguy, Cao, Hongyuan, Dignam, James, Bychkovsky, Brittany Louise, Finkelstein, Dianne Madelyn, Guindalini, Rodrigo Santa Cruz, Nunes Filho, Paulo Ricardo Santos, Silva, Caroline Albuquerque Moreira da, Reinert, Tomás, Azambuja, Evandro de, Olopade, Olufunmilayo L.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/181142
• topic: Neoplasias da mama; Receptor erbB-2; Trastuzumab; Quimioterapia adjuvante; Breast cancer; HER2/ERBB2; Adjuvant treatment; Neoadjuvant treatment; Meta-analysis; Network meta-analysis

Background: Several (neo)adjuvant treatments for patients with HER2-positive breast cancer have been compared in different randomized clinical trials. Since it is not feasible to conduct adequate pairwise comparative trials of all these therapeutic options, network meta-analysis offers an opportunity for more detailed inference for evidence-based therapy. Methods: Phase II/III randomized clinical trials comparing two or more different (neo) adjuvant treatments for HER2-positive breast cancer patients were included. Relative treatment effects were pooled in two separate network meta-analyses for overall survival (OS) and disease-free survival (DFS). Results: 17 clinical trials met our eligibility criteria. Two different networks of trials were created based on the availability of the outcomes: OS network (15 trials: 37,837 patients); and DFS network (17 trials: 40,992 patients). Two studies—the ExteNET and the NeoSphere trials—were included only in this DFS network because OS data have not yet been reported. The concept of the dual anti-HER2 blockade proved to be the best option in terms of OS and DFS. Chemotherapy (CT) plus trastuzumab (T) and lapatinib (L) and CT + T + Pertuzumab (P) are probably the best treatment options in terms of OS, with 62.47% and 22.06%, respectively. In the DFS network, CT + T + Neratinib (N) was the best treatment option with 50.55%, followed by CT + T + P (26.59%) and CT + T + L (20.62%). Conclusion: This network meta-analysis suggests that dual anti-HER2 blockade with trastuzumab plus either lapatinib or pertuzumab are probably the best treatment options in the (neo)adjuvant setting for HER2-positive breast cancer patients in terms of OS gain. Mature OS results are still expected for the Aphinity trial and for the sequential use of trastuzumab followed by neratinib, the treatment that showed the best performance in terms of DFS in our analysis.